UBS Group
NRSN icon

UBS Group’s NeuroSense Therapeutics NRSN Stock Holding History

UBS Group’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.36K Sell
985
-4,447
-82% -$43.2K ﹤0.01% 9685
2026
Q2 		$78.2K Buy
5,432
+2,977
+121% +$46.4K ﹤0.01% 7320
2026
Q1 		$37.1K Buy
2,455
+911
+59% +$16.3K ﹤0.01% 7557
2025
Q4 		$23.7K Buy
1,544
+811
+111% +$17.1K ﹤0.01% 7666
2025
Q3 		$18.3K Buy
733
+652
+805% +$19.1K ﹤0.01% 8210
2025
Q2 		$3.04K Sell
81
-33
-29% -$956 ﹤0.01% 9391
2025
Q1 		$2.12K Buy
+114
New +$2.52K ﹤0.01% 9386
2024
Q2 		– Sell
-596
Closed -$21.7K – 9920
2024
Q1 		$21.7K Buy
596
+321
+117% +$8.64K ﹤0.01% 6892
2023
Q4 		$4.31K Sell
275
-208
-43% -$2.76K ﹤0.01% 7877
2023
Q3 		$6.86K Buy
+483
New +$10.1K ﹤0.01% 7266
2023
Q2 		– Sell
-238
Closed -$8.19K – 9407
2023
Q1 		$8.19K Buy
238
+35
+17% +$1.16K ﹤0.01% 7748
2022
Q4 		$4.96K Buy
203
+112
+123% +$3.56K ﹤0.01% 9238
2022
Q3 		$3K Sell
91
-580
-86% -$23.8K ﹤0.01% 9562
2022
Q2 		$45K Buy
671
+577
+614% +$21.9K ﹤0.01% 6003
2022
Q1 		$7K Sell
94
-307
-77% -$14.6K ﹤0.01% 8829
2021
Q4 		$20K Buy
+401
New +$24.4K ﹤0.01% 7843

Other funds holding NRSN

PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

UBS Group's NRSN Position: Q3 2026 in Review

UBS Group reduced its NeuroSense Therapeutics (NRSN) stake by 82% in Q3 2026, selling an estimated $43.2K and leaving 985 shares worth $4.36K. The position accounts for ﹤0.01% of the portfolio, ranked #9685.

UBS Group first reported a position in NRSN in Q4 2021 and has held it in 16 quarters since. The position peaked at $78.2K in Q2 2026. 4 funds tracked by Wall St. Rank hold NRSN as of Q3 2026.

  • UBS Group held 985 shares of NeuroSense Therapeutics worth $4.36K as of Q3 2026.
  • UBS Group sold 4,447 NeuroSense Therapeutics shares in Q3 2026, an estimated $43.2K.
  • NeuroSense Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #9685 holding.
  • UBS Group first reported a position in NeuroSense Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • UBS Group's NeuroSense Therapeutics position peaked at $78.2K in Q2 2026.
  • 4 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.